Xenon to Present at Upcoming Investor Conferences

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18 at 9:10 a.m. ET and the Jefferies London Healthcare Conference 2024 on November 20 at 1:30 PM GMT / 8:30 am ET.

Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications. Webcasts of the presentations will be available on Xenon's website investor section.

News Market Reaction

-0.52%

1 alert

-0.52% News Effect

On the day this news was published, XENE declined 0.52%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.

• Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 9:10 a.m. ET (webcast link)
• Jefferies London Healthcare Conference 2024 on Wednesday, November 20, 2024 at 1:30 PM GMT / 8:30 am ET (webcast link)

Details about company presentations, webcasts, and other events can be found on the “Investors” section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals (XENE) present at the Stifel Healthcare Conference 2024?

Xenon Pharmaceuticals will present at the Stifel Healthcare Conference on Monday, November 18, 2024, at 9:10 a.m. ET.

What is Xenon Pharmaceuticals' (XENE) main product in development?

Azetukalner, a Kv7 potassium channel opener, is Xenon's most advanced product in late-stage clinical development for multiple indications.

Which therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?

Xenon Pharmaceuticals focuses on neuroscience, specifically developing treatments for epilepsy and depression through ion channel products.

When is Xenon's (XENE) presentation at the Jefferies London Healthcare Conference 2024?

Xenon will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 PM GMT / 8:30 am ET.